LUNG TRANSPLANT RECIPIENT Clinical Trials

18 clinical trials for LUNG TRANSPLANT RECIPIENT across international registries, including 7 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Combination Letermovir and Standard of Care Antiviral for Enhanced Antiviral Response in Cytomegalovirus Infection in Lung Transplant Recipients — RECRUITING · PHASE4
• Combined Light, ExVivo, and Antivirals for Recipients of Lungs From HBV Donors — RECRUITING · PHASE4
• A PHASE 2B, NON-RANDOMIZED, CONTROLLED, OPEN-LABEL, EXTENSION STUDY TO EVALUATE THE PERSISTENCE OF IMMUNE RESPONSE OF THE ADJUVANTED RSVPREF3 VACCINE AND THE SAFETY AND IMMUNOGENICITY FOLLOWING REVACCINATION IN LUNG AND KIDNEY TRANSPLANT RECIPIENTS (¿18 YEARS OF AGE) — RECRUITING · PHASE2
• BELUMOSUDIL TO BLOCK CLAD IN HIGH RISK LUNG TRANSPLANT RECIPIENTS: A RANDOMIZED, MULTICENTER, DOUBLE BLIND, PLACEBO-CONTROLLED TRIAL — RECRUITING
• SAFETY AND IMMUNOGENICITY OF NON-LIVE, ADJUVANTED RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE IN ALLOGENEIC STEM CELL TRANSPLANT AND LUNG TRANSPLANT RECIPIENTS — RECRUITING
• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, PHASE 3 STUDY, FOLLOWED BY OPEN-LABEL EXTENSIONS, TO EVALUATE THE EFFICACY OF ORAL BELUMOSUDIL IN ADULT PARTICIPANTS WITH CHRONIC LUNG ALLOGRAFT DYSFUNCTION (CLAD) FOLLOWING BILATERAL LUNG TRANSPLANTATION — RECRUITING · PHASE3
• A PHASE 2B, RANDOMIZED, CONTROLLED, OPEN-LABEL STUDY TO EVALUATE THE IMMUNE RESPONSE AND SAFETY OF THE RSVPREF3 OA INVESTIGATIONAL VACCINE IN ADULTS (¿50 YEARS OF AGE) WHEN ADMINISTERED TO LUNG AND RENAL TRANSPLANT RECIPIENTS COMPARING 1 VERSUS 2 DOSES AND COMPARED TO HEALTHY CONTROLS (¿50 YEARS OF AGE) RECEIVING 1 DOSE — RECRUITING · PHASE2
• BRIDGE - Blocking Receptor of IL-1β for Donor Graft Edema Reduction — NOT_YET_RECRUITING · PHASE1
• Tubeless Strategy in Lung Transplantation: A Prospective Single-Arm Study — COMPLETED · NA
• CLEAR-CMV: COMBINATION LETERMOVIR AND STANDARD OF CARE ANTIVIRAL FOR ENHANCED ANTIVIRAL RESPONSE IN CYTOMEGALOVIRUS INFECTION IN LUNG TRANSPLANT RECIPIENTS: A PILOT TRIAL [PLACEBO CONTROLLED] — NOT_YET_RECRUITING
• LUNG TRANSPLANTATION USING HEPATITIS B POSITIVE DONORS TO HEPATITIS B NEGATIVE RECIPIENTS USING EX-VIVO TREATMENT OF ORGANS: A SAFETY TRIAL — NOT_YET_RECRUITING
• High-Dose Moderna mRNA-1273 Booster Study for Lung Transplant Recipients — TERMINATED · PHASE1
• TARGETING INFLAMMATION AND ALLOIMMUNITY IN LUNG TRANSPLANT RECIPIENTS WITH TOCILIZUMAB (ALL IN LUNG) — COMPLETED
• HYPERPOLARIZED 129XE MAGNETIC RESONANCE IMAGING FOR EVALUATION OF CHRONIC LUNG ALLOGRAFT DYSFUNCTION IN LUNG TRANSPLANT RECIPIENTS — COMPLETED
• DSA Intragraft in Lung Transplantation: Diagnostic and Prognostic Value in Antibody Mediated Rejection — OTHER · NA
• A RANDOMIZED CONTROLLED OPEN-LABEL STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF NEBULIZED PC945 FOR PROPHYLAXIS OR PREEMPTIVE THERAPY AGAINST PULMONARY ASPERGILLOSIS IN LUNG TRANSPLANT RECIPIENTS — COMPLETED
• EX-VIVO DELIVERY OF RITUXIMAB TO PREVENT PTLD IN EBV MISMATCH LUNG TRANSPLANT RECIPIENTS: A PILOT TRIAL — NOT_YET_RECRUITING
• Safety and Efficacy Study of Inhaled AmBisome for Prevention of Aspergillus Colonization in Lung Transplant Recipients — SUSPENDED · PHASE2

Refine this search